Interaction between the Amino- and Carboxyl-terminal Regions of the Rat Androgen Receptor Modulates Transcriptional Activity and Is Influenced by Nuclear Receptor Coactivators*
- From the ‡Department of Physiology, Institute of Biomedicine and the §Department of Clinical Chemistry, University of Helsinki, FIN-00014 Helsinki, Finland
Abstract
Identical N-terminal deletions in the wild-type rat androgen receptor (rAR) and a constitutively active rAR (ARΔ641–902) devoid of the ligand-binding domain (LBD) resulted in dissimilar consequences in transcriptional activation: deletion of residues 149–295 abolished wild-type AR activity, but did not influence that of ARΔ641–902. The activity of the N-terminal transactivation domain is thus controlled by the hormone-occupied LBD, suggesting that the N- and C-terminal regions of rAR communicate. Consistent with this idea, a strong androgen-dependent interaction between the N-terminal region and LBD was demonstrated in a mammalian two-hybrid system using GAL4 and VP16 fusion proteins. This interaction can be direct or indirect. Several nuclear receptor coactivators (CBP, F-SRC-1, SRC-1, and RIP140) that interact with other steroid receptors were tested as potential mediators of the N- and C-terminal interaction of rAR using the mammalian two-hybrid system. CBP or F-SRC-1 not only enhanced AR-mediated transactivation, but also facilitated the androgen-dependent interaction between the N- and C-terminal domains, implying that part of the coactivator-dependent transcriptional activation occurs via this mechanism. In contrast, SRC-1, a coactivator for the progesterone receptor, inhibited both AR-mediated transactivation and interaction between the N and C termini. Recruitment of coregulators may involve AR domains other than the LBD, as F-SRC-1 and CBP enhanced, but SRC-1 repressed, the transcriptional activity of ARΔ641–902. Collectively, interplay between the N-terminal region and LBD of rAR results in the formation of a transactivation complex that includes coregulators and that is mandatory for optimal activation of androgen-induced promoters.
Footnotes
-
↵* This work was supported by grants from the Medical Research Council of the Academy of Finland, the Emil Aaltonen Foundation, the Finnish Foundation for Cancer Research, the Jalmari and Rauha Ahokas Foundation, and the University of Helsinki.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
↵¶ To whom correspondence should be addressed: Dept. of Physiology, Inst. of Biomedicine, University of Helsinki, P. O. Box 9 (Siltavuorenpenger 20 J), FIN-00014 Helsinki, Finland. Tel.: 358-9-1918544; Fax: 358-9-1918681; E-mailolli.janne{at}helsinki.fi.
-
↵1 The abbreviations used are: AR, androgen receptor; rAR, rat AR; hAR, human AR; ARE, androgen response element; DBD, DNA-binding domain; LBD, ligand-binding domain; GR, glucocorticoid receptor; PR, progesterone receptor; hPR, human PR; MR, mineralocorticoid receptor; ER, estrogen receptor; PCR, polymerase chain reaction; CHO, Chinese hamster ovary; DOTAP,N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl sulfate; PAS, Per/Arnt/Sim.
-
- Received July 10, 1997.
- Revision received September 11, 1997.











